Diarylquinolines target subunit c of mycobacterial ATP synthase
Top Cited Papers
- 13 May 2007
- journal article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 3 (6), 323-324
- https://doi.org/10.1038/nchembio884
Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.Keywords
This publication has 12 references indexed in Scilit:
- A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910Proteins-Structure Function and Bioinformatics, 2007
- In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulceransAntimicrobial Agents and Chemotherapy, 2006
- Mass spectrometry of the M. smegmatis proteome: Protein expression levels correlate with function, operons, and codon biasGenome Research, 2005
- The F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for GrowthJournal of Bacteriology, 2005
- Nature's Rotary ElectromotorsScience, 2005
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- The membrane-associated F0F1ATPase is essential for the viability ofStreptococcus pneumoniaeFEMS Microbiology Letters, 2002
- Molecular mechanisms that confer antibacterial drug resistanceNature, 2000
- Global Burden of TuberculosisJAMA, 1999
- The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutolNature Medicine, 1997